Skip to content
Fat BurnerWADA ProhibitedCompare

Albuterol

Also known as: Salbutamol, Ventolin, ProAir, Proventil

5
1 · Natty510 · Enhanced

Lower numbers = closer to natural. Higher numbers = more enhanced.

Why this rating?

Albuterol is an FDA-approved beta-2 agonist bronchodilator. Beta-2 stimulation dose-dependently raises resting metabolic rate (roughly 10-50% in studies of beta-2 agonists) and, via cAMP/calpastatin, inhibits calpain-driven muscle breakdown. Controlled human trials in muscular dystrophy patients (e.g. PubMed 17942817, 9595995) showed real but modest lean-mass gains and fat-mass reductions over months, nowhere near the eye-catching 19% muscle / up to 39% fat figures from the rat study (PubMed 7916118) that community sources love to cite. WADA prohibits oral use at all times (only inhaled, within limits, is permitted), so it is a genuine prohibited-substance stimulant with real systemic metabolic and anti-catabolic effects, but a narrower, milder profile than clenbuterol (rated 6) given its shorter half-life and faster-clearing, less potent beta agonism. Rated 5 to sit alongside other stimulant/thyroid-tier fat burners (ephedrine, T3) rather than clenbuterol's tier.

Overview

A selective beta-2 adrenergic agonist, roughly 29-fold more selective for beta-2 vs beta-1 receptors. Often considered a safer alternative to clenbuterol due to a much shorter half-life (5-6 hrs vs ~26-48 hrs) and better cardiac profile. Works through the cAMP pathway to promote lipolysis and exhibits anti-catabolic effects by inhibiting calpain (a muscle protein-degradation enzyme). Rat studies show a 19% muscle mass increase and 12-39% fat reduction; the effect in humans is real but far more modest.

Important Warnings

  • •WADA prohibits oral forms at all times - only inhaled permitted with limits
  • •Do not exceed 16mg/day
  • •Cycle max 8 weeks, then 2+ weeks off for receptor upregulation
  • •Avoid with cardiovascular disease
  • •Monitor potassium especially with diuretics or corticosteroids
  • •May cause hyperglycemia via glycogenolysis
  • •Tolerance develops over 2-4 weeks - requires cycling
  • •Do not combine with other beta agonists (clenbuterol)
  • •Pre-existing cardiac conditions are contraindication for off-label use

Purpose & Use Cases

Fat Loss

Stimulates beta-2 receptors to increase energy expenditure and lipolysis. Beta-2 agonists can raise resting metabolic rate meaningfully in the short term, but controlled human data show a modest effect (e.g. one RCT found fat-mass loss in trained women but not men over 6 weeks). Treat it as a mild-to-moderate assist alongside diet, not a dramatic fat-loss driver.

Anti-Catabolic/Muscle Preservation

Inhibits calpain (muscle degradation enzyme) via cAMP/calpastatin. Rat studies: 19% increase in hindlimb muscle weight. Controlled human trials in muscular dystrophy patients (DEXA-measured) showed statistically significant, modest lean-mass gains and fat-mass reductions over 12 weeks to a year of use.

Safer Clenbuterol Alternative

5-6 hour half-life (vs roughly 26-48 hrs for clen) allows the body to recover overnight. No cardiac lesions have been documented for albuterol at therapeutic doses, unlike the cardiac fibrosis/hypertrophy seen with chronic clenbuterol in animal models.

Bronchodilation

Primary FDA-approved use. Opens airways within 5 minutes when inhaled. 7th most prescribed medication in USA.

Benefits

  • Shorter half-life than clenbuterol (5-6 hrs vs roughly 26-48 hrs)
  • Better cardiac safety profile - no cardiac lesions documented
  • FDA-approved for human use (unlike clen in USA)
  • Slower tolerance development - can use longer before cycling
  • Anti-catabolic: inhibits calpain, preserves muscle
  • May provide small strength increase (unlike clen which can reduce strength)
  • Milder CNS stimulation - better workout focus
  • Rat studies: 19% muscle mass increase, up to 39% fat reduction

Good to Know

The "milder, more forgiving clenbuterol"

Albuterol is highly beta-2 selective and clears in ~5-6 hours (vs clenbuterol's 26-48h), so the body recovers overnight and no cardiac lesions have been documented at therapeutic doses, unlike clen. The trade-off is a milder effect and more frequent dosing. It is the sensible pick if you want a beta-2 fat-loss agent with a better safety margin.

For tested athletes: oral is banned, inhaled is allowed within limits

WADA prohibits ORAL salbutamol/albuterol at all times, but permits INHALED use up to 1600mcg/24h (max ~600mcg per 8h) with a urinary threshold of 1000ng/mL. Physique users take it orally, which is the prohibited route. The asthma-inhaler exemption does not cover fat-loss dosing.

Hypokalemia is the sign to watch

Beta-2 activation drives potassium into cells, so cramps, weakness and palpitations often trace back to low potassium/magnesium rather than the drug "not agreeing with you." Replenish electrolytes, and be extra careful if you also use diuretics or corticosteroids.

The muscle-building numbers are from rats

The eye-catching "19% muscle gain / 39% fat loss" figures come from rodent studies. In humans, albuterol is a modest fat-loss and mild muscle-preservation tool (via calpain inhibition), not a muscle builder. Set expectations accordingly.

Dosage Guidelines

Experience LevelDosage Range
Beginner4 – 8 mg/day
Intermediate8 – 12 mg/day
Advanced12 – 16 mg/day
Frequency
2-3x daily oral tablets, space doses evenly (immediate-release ~5-6h half-life).
Typical Cycle Length
4 – 8 weeks
Notes

Standard dose: 4mg 2-3x daily (8-12mg/day). Community-cited ceiling ~16mg/day (matches the sustained-release 16mg/day dose used in published muscular dystrophy trials); do not treat higher amounts as safe. Females: ~6mg/day in split doses is a common community figure. Cycle max ~8 weeks, then 2+ weeks off for beta-2 receptor upregulation. Ketotifen can be used to upregulate receptors during extended use. Albuterol 4mg + caffeine 100mg, 3x daily, is a commonly cited combo (Pennington Biomedical rat + human research): the rat data showed better lean-mass/fat-mass outcomes than albuterol alone, but the human metabolic-rate study found no clear synergy, just an additive effect.

Side Effects

Tremors/Shakiness

common
Severity
2/5

~20% incidence. Beta-2 activation on motor nerve terminals increases intracellular cAMP.

Mitigation

Usually diminishes over 1-2 weeks. Start with lower dose.

Tachycardia

uncommon
Severity
2.5/5

<10% incidence. Cardiac beta receptor stimulation increases heart rate.

Mitigation

Monitor heart rate. Reduce dose if persistent. Avoid if cardiovascular issues.

Hypokalemia

uncommon
Severity
2.5/5

Intracellular shift of potassium via Na,K-ATPase stimulation on skeletal muscle.

Mitigation

Monitor potassium. Supplement if needed. Avoid with diuretics/corticosteroids.

Nervousness/Anxiety

common
Severity
2/5

CNS stimulation. Generally milder than with clenbuterol.

Mitigation

Usually transient. Reduce dose if severe.

Muscle Cramps

common
Severity
1.5/5

Related to electrolyte shifts.

Mitigation

Stay hydrated. Supplement potassium, magnesium, taurine.

Headache

uncommon
Severity
1.5/5

Vasodilation effects.

Mitigation

Usually transient.

General Mitigation Strategies

Shorter half-life (5-6 hrs) means side effects clear faster than with clenbuterol. Tremors typically diminish over 1-2 weeks. Monitor potassium especially if using diuretics or corticosteroids. Better cardiac safety than clenbuterol - no cardiac lesions documented at therapeutic doses. CNS stimulation is milder, allowing better focus during training.

Support Supplements

Ancillary supplements commonly run alongside Albuterol to manage side effects, support the target tissue, or fill nutrient demands it creates.

Potassium + magnesium (electrolytes)

Key

Beta-2 stimulation shifts potassium into cells (hypokalemia), which drives cramps and can add to palpitations. Replenishing potassium and magnesium addresses the most common albuterol complaints.

Dose
Adequate dietary potassium; magnesium 300-400mg/day
Timing
Daily
When
Especially important if also using diuretics or corticosteroids, which deepen potassium loss.

Taurine

As with clenbuterol, taurine helps the beta-2-agonist muscle cramps and may ease tremor. Cheap, low-risk support.

Dose
3-5g/day
Timing
Split through the day

Ketotifen (fumarate)

Restores beta-2 receptor density to counter the downregulation that eventually blunts albuterol's effect, allowing longer runs without cycling off.

Dose
1-2mg at night
Timing
Before bed (sedating)
When
Optional, for extending cycle length; albuterol downregulates receptors more slowly than clenbuterol, so it is less often needed.

Post Cycle Therapy (PCT)

✓PCT Not Required

Does not affect HPT axis. No PCT required. Receptor downregulation occurs - cycle off 2+ weeks between uses.

How It Works

Stimulates beta-2 adrenergic receptors, activating adenylate cyclase through G proteins, increasing intracellular cAMP. cAMP/PKA signaling increases calpastatin activity, which inhibits calpain (a protease that degrades muscle protein), providing anti-catabolic effects. Also stimulates glycogenolysis and lipolysis. Roughly 29-fold more selective for beta-2 than beta-1 receptors, providing a better cardiac safety profile than non-selective beta agonists.

Fundamentals

Reference on the practices relevant to Albuterol: how they are done and where they go wrong. Not a recommendation to use it.

Bloodwork: what to measure and when→

The markers that matter here

Warning signs & when to seek care→

When to stop and get help

Common Stacks

  • Albuterol 4mg + Caffeine 100mg (3x daily) - rat data show better lean/fat outcomes than albuterol alone; human data show an additive, not clearly synergistic, effect
  • Albuterol + Ketotifen (1mg before bed) - upregulates beta-2 receptors for extended use
  • Albuterol + T3 - enhanced fat loss (but increased side effect risk)
  • DO NOT combine with Clenbuterol - both beta-2 agonists
  • Use caution with diuretics - increases hypokalemia risk

WADA Status

⛔Prohibited by WADA
Category: S3. Beta-2 Agonists
In-Competition: ProhibitedOut-of-Competition: Prohibited

Salbutamol (Albuterol) is prohibited except when inhaled at therapeutic doses (max 1600mcg/24hrs). Urinary concentration must not exceed 1000ng/mL.

References

Last updated: July 18, 2026